1 / 7

Acute Lung Injury-Pipeline Insights, 2014 - with 50% Discount

Bharatbook.com announces 20% discount on various market research reports, which combine industry expertise with innovation by collecting, analyzing and communicating to deliver critical information to leading decision makers in the Approved drugs market, Active Pharmaceutical (API) market, Generic market and Drug’s research and development. It also help Drug developing companies, Generics and API manufacturing companies to strategize and identify the right thrust areas and potential customers for their existing and new products. Hurry Up!!! (Offer valid till 26th Dec., 2014)

bharatbookseo
Download Presentation

Acute Lung Injury-Pipeline Insights, 2014 - with 50% Discount

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Acute Lung Injury-Pipeline Insights, 2014 - with 50% Discount One-Stop Shop for Business Information

  2. Summary SUMMARY 'Acute Lung Injury-Pipeline Insights, 2014', report provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under Acute Lung Injury. This report provides information on the therapeutic development based on the Acute Lung Injury dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information. The report also covers the companies information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

  3. Secondary sources information and data has been collected from various printable and non-printable sources like search engines, News websites, Government Websites, Trade Journals, White papers, Magazines, Trade associations, Books, Industry Portals, Industry Associations and access to available databases. Scope • The report provides a snapshot of the global therapeutic landscape of Acute Lung Injury • The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information • Coverage of the Acute Lung Injury pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

  4. • The report reviews key players involved in the therapeutics development for Acute Lung Injury and also provide company profiling • The report also gives the information of dormant and discontinued pipeline projects • Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages • Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type Reasons to buy • Complete Pipeline intelligence and complete understanding over therapeutics development for Acute Lung Injury • Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine.

  5. • Devise corrective measures for pipeline projects by understanding Acute Lung Injury pipeline depth and focus of Indication therapeutics • Developing strategic initiatives to support your drug development activities. • Optimize your portfolio and keep you in touch with the rapidly changing pharmaceutical markets, and make the best decisions for your business. • Develop and design in licensing and out licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline• Gaining a Full Picture of the Competitive Landscape for Evidence based Decisions

  6. Table Of Content • Acute Lung Injury Overview • Acute Lung Injury Pipeline Therapeutics • Acute Lung Injury Therapeutics under Development by Companies • Acute Lung Injury Late Stage Products (Filed and Phase III) • Comparative Analysis • Acute Lung Injury Mid Clinical Stage Products (Phase II) • Comparative Analysis • Acute Lung Injury Early Clinical Stage Products (Phase I and IND Filed) • Comparative Analysis • Acute Lung Injury Discovery and Pre-Clinical Stage Products • Comparative Analysis • Drug Candidate Profiles • Acute Lung Injury – Therapeutics Assessment • Assessment by Monotherapy Products • Assessment by Combination Products

  7. To know more :Acute Lung Injury-Pipeline Insights, 2014 Contact Us:-Call India: +91-22-27810772/73 Call USA/Canada (Toll Free): 1-866-279-8368 Email id : info@bharatbook.com

More Related